Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Opens New Biopharmaceutical CDMO Facility In North America


FUJIFILM Diosynth Biotechnologies plans for the construction of largest cell culture biophramaceutical CDMO facility. The facility will be located in North America.


The new, state-of-the-art facility consists of large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors.

This facility having the potential to expand will add further 24 x 20,000L bioreactors. Moreover, it expands and further add  24 x 20,000L bioreactors.

The new biopharmaceutical facility also consists of automated fill-finish, commercial-scale, packaging and labelling services. In addition, the new facility will have the ability to produce life-impacting medicines.

The new facility is expected to be completed and fully opeartional by spring 2025. Once the construction is completed it is expected to create 725 new jobs.


NameFUJIFILM Diosynth Biotechnologies
TypeNew Construction
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference